---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-109587"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2026-10-15T12:00:17+00:00"
generated_at: "2026-10-15T12:05:13.473955+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Jasper Therapeutics completes IgAN enrollment for vensobafusp alfa Phase 2; adds FSGS cohort

## Summary
- 18 IgAN patients enrolled in stage 1 across 3 cohorts: subcutaneous Q2W (n=6), Q4W (n=6) and Q8W (n=6) maintenance dosing.
- Initial interim IgAN data from the Phase 2 basket study expected by year-end 2026; stage 1 assesses safety, tolerability and initial efficacy.
- New FSGS cohort added to the basket study, with first patients anticipated to be dosed in the first quarter of 2027.
- Study runs in China with partner Kira; vensobafusp alfa (KP104) is a bifunctional biologic targeting both alternative and terminal complement pathways.
- CMO Greg Keenan said enrollment completed on schedule; company is exploring additional cohorts in other complement-mediated kidney diseases.

## SEC filing metadata
- accession: 0001213900-26-109587
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2026-10-15T12:00:17+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390026109587/0001213900-26-109587-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390026109587/ea0308657-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-109587
- JSON: https://secwatch.observer/filing/0001213900-26-109587.json
- Plain text: https://secwatch.observer/filing/0001213900-26-109587.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.